Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Rhea-AI Summary

Nautilus Biotechnology (NASDAQ: NAUT) will report fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026. Management will host a webcast and conference call to discuss results, business developments, and outlook.

Live audio will be available on the company’s Investors webpage at www.nautilus.bio.

News Market Reaction

-2.88%

1 alert

-2.88% News Effect

On the day this news was published, NAUT declined 2.88%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings period: Fourth quarter and full year 2025 Earnings date: February 26, 2026 Conference time PT: 5:30 a.m. Pacific Time +1 more

4 metrics

Earnings period Fourth quarter and full year 2025 Period for upcoming results

Earnings date February 26, 2026 Scheduled results release before market open

Conference time PT 5:30 a.m. Pacific Time Start of management webcast

Conference time ET 8:30 a.m. Eastern Time Start of management webcast

Market Reality Check

Price: $2.03 Vol: Volume 137,898 is below t...

low vol

$2.03 Last Close

Volume Volume 137,898 is below the 20-day average of 226,683 (relative 0.61x). low

Technical Price $2.08 is trading above the 200-day MA of $1.18.

Peers on Argus

NAUT fell 2.8% while peers were mixed: QNCX up 8.43%, IPA up 3.5%, CSBR down 7.1...

1 Up

NAUT fell 2.8% while peers were mixed: QNCX up 8.43%, IPA up 3.5%, CSBR down 7.19%, EXOZ and SEER modestly negative, suggesting stock-specific factors rather than a broad sector move.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Research partnership	Positive	-7.6%	Parkinson’s biomarker collaboration backed by <b>$1.6 million</b> MJFF grant.
Jan 08	Early access launch	Positive	+0.0%	Launch of early access program for single-molecule proteomics tau assay.
Nov 03	Field unit deployment	Positive	+39.1%	First external field evaluation unit installed and tested with reproducible data.
Oct 28	Q3 2025 earnings	Positive	+5.9%	Q3 2025 results with reduced expenses and substantial cash balance reported.
Oct 07	Earnings date notice	Neutral	+0.1%	Announcement of timing for Q3 2025 earnings release and webcast details.

Pattern Detected

Recent fundamentally positive updates, including collaborations and platform milestones, have sometimes met with flat or negative next-day reactions, while major platform validation and earnings results have seen stronger positive alignment.

Recent Company History

Over the last few months, Nautilus reported several key milestones. A Jan 28, 2026 Parkinson’s research collaboration supported by a $1.6 million grant saw a -7.62% move, while the early access program launch on Jan 8, 2026 produced a flat reaction. Installation of the first field evaluation unit on Nov 3, 2025 coincided with a 39.1% gain. Q3 2025 earnings on Oct 28, 2025 led to a 5.93% rise, whereas the prior Q3 earnings date notice on Oct 7, 2025 had minimal impact.

Market Pulse Summary

This announcement sets expectations for Nautilus’ upcoming fourth quarter and full year 2025 results...

Analysis

This announcement sets expectations for Nautilus’ upcoming fourth quarter and full year 2025 results, scheduled for February 26, 2026 with a management webcast at 5:30 a.m. PT / 8:30 a.m. ET. Recent history shows meaningful stock moves around substantive milestones like platform validation and quarterly reports, while timing notices alone have had limited impact. Investors may focus on how the forthcoming details build on prior progress in collaborations, early access programs, and operating discipline.

Key Terms

single-molecule protein analysis platform, webcast

2 terms

single-molecule protein analysis platform medical

"a company pioneering a single-molecule protein analysis platform, today announced"

A single-molecule protein analysis platform is a laboratory technology that detects and measures individual protein molecules rather than averaging many at once, like counting each person in a crowd instead of estimating crowd size. For investors, it matters because that higher sensitivity and precision can enable earlier disease detection, more accurate diagnostics and tighter drug development control, potentially creating faster paths to market and stronger competitive advantage in biotech and diagnostics markets.

webcast technical

"The company’s management will webcast a corresponding conference call"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026.

The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

FAQ

When will Nautilus (NAUT) report fourth quarter and full year 2025 results?

The company will report results before market open on February 26, 2026. According to Nautilus, the release covers fourth quarter and full year 2025 and precedes a management webcast and conference call to discuss results and outlook.

What time is the Nautilus (NAUT) conference call and webcast on February 26, 2026?

The management webcast and conference call begins at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. According to Nautilus, the call will follow the results release and cover business developments and company outlook.

Where can investors access the Nautilus (NAUT) earnings webcast?

Live audio of the webcast will be available on the Investors section of the company website at www.nautilus.bio. According to Nautilus, investors should use that page to access the live audio for the February 26, 2026 presentation.

What will Nautilus management discuss during the February 26, 2026 call?

Management will discuss fourth quarter and full year 2025 results, business developments, and the company outlook. According to Nautilus, the webcast and call are intended to explain results and provide forward-looking context for investors.